Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 13.04B 11.43B 10.56B 9.75B 18.49B 1,248B 18.86B 127B 49.31B 611B 48.95B 47.88B 2,120B P/E 2026 *
-81.1x
P/E 2027 * 57.2x
Enterprise Value 12.51B 10.97B 10.13B 9.36B 17.74B 1,198B 18.09B 122B 47.3B 586B 46.97B 45.94B 2,034B EV / Sales 2026 *
8.36x
EV / Sales 2027 * 5.41x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day+3.67%
1 week+9.92%
Current month+5.30%
1 month+21.00%
3 months+8.78%
6 months+1.65%
Current year-2.91%
1 week 522.06
Extreme 522.06
566.68
1 month 460.89
Extreme 460.89
566.68
Current year 416.21
Extreme 416.21
598.79
1 year 286.44
Extreme 286.44
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 07/09/2023
Director of Finance/CFO 62 10/03/2024
Chief Tech/Sci/R&D Officer 58 20/04/2025
Director TitleAgeSince
Director/Board Member 74 30/06/2016
Director/Board Member 68 10/08/2016
Director/Board Member 64 26/06/2019
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Founder

1,220 0.0053%
06-16Free

Director

1,085 0.0047%
06-16
Baker Bros. Advisors LP
FreeCompany 4,880 0.0212%
Change 5-day change 1-year change 3-year change Capi.($)
+3.67%+9.92%+96.65%+158.02% 12.57B
-1.53%+0.78%+72.33%+129.70% 57.72B
-2.45%-7.83%+63.92%+83.15% 52.65B
+3.27%+8.91%+21.21%+486.76% 24.46B
-0.81%-0.42%-16.24%-12.47% 23.84B
+4.71%+4.02%+44.02%-1.84% 19.28B
-0.24%+5.11%+38.76%-26.41% 17.8B
+2.34%+12.50%+224.02%+380.99% 17.29B
-1.38%+1.24%+35.33% - 15.28B
-1.70%+3.98%+28.96%+190.57% 14.35B
Average +0.59%+5.95%+60.90%+154.27% 25.52B
Weighted average by Cap. -0.11%+3.46%+59.76%+142.82%

Financials

2026 *2027 *
Net sales 1.5B 1.31B 1.21B 1.12B 2.12B 143B 2.16B 14.56B 5.66B 70.07B 5.62B 5.49B 243B 2.21B 1.93B 1.79B 1.65B 3.13B 211B 3.19B 21.48B 8.34B 103B 8.28B 8.1B 359B
Net income -201M -176M -163M -150M -285M -19.25B -291M -1.96B -760M -9.42B -755M -738M -32.7B 308M 270M 249M 230M 436M 29.46B 445M 3B 1.16B 14.42B 1.16B 1.13B 50.05B
Net Debt -529M -464M -429M -396M -751M -50.67B -766M -5.15B -2B -24.8B -1.99B -1.94B -86.08B -1.09B -960M -886M -819M -1.55B -105B -1.58B -10.66B -4.14B -51.29B -4.11B -4.02B -178B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
08/07/26 US$565.40 +3.67% 468,222
07/07/26 US$545.36 +3.00% 318,420
06/07/26 US$529.48 +0.26% 230,982
02/07/26 US$528.10 +2.67% 221,894
01/07/26 US$514.39 -4.20% 303,751
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
565.40USD
Average target price
678.71USD
Spread / Average Target
+20.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock